|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MARCKSL1 |
Gene summary for MARCKSL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MARCKSL1 | Gene ID | 65108 |
| Gene name | MARCKS like 1 | |
| Gene Alias | F52 | |
| Cytomap | 1p35.1 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | P49006 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65108 | MARCKSL1 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 2.60e-37 | 1.57e+00 | -0.1833 |
| 65108 | MARCKSL1 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 6.18e-29 | 1.54e+00 | -0.23 |
| 65108 | MARCKSL1 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 1.60e-25 | 1.89e+00 | -0.23 |
| 65108 | MARCKSL1 | 047563_1562-all-cells | Human | Prostate | BPH | 1.02e-09 | -1.13e-01 | 0.0791 |
| 65108 | MARCKSL1 | 048752_1579-all-cells | Human | Prostate | BPH | 2.43e-03 | 1.35e-01 | 0.1008 |
| 65108 | MARCKSL1 | Dong_P1 | Human | Prostate | Tumor | 8.88e-76 | 9.62e-01 | 0.035 |
| 65108 | MARCKSL1 | Dong_P3 | Human | Prostate | Tumor | 2.09e-17 | 5.37e-01 | 0.0278 |
| 65108 | MARCKSL1 | Dong_P4 | Human | Prostate | Tumor | 4.10e-18 | 8.80e-01 | 0.0292 |
| 65108 | MARCKSL1 | Dong_P5 | Human | Prostate | Tumor | 1.32e-55 | 9.04e-01 | 0.053 |
| 65108 | MARCKSL1 | Dong_P6 | Human | Prostate | Tumor | 3.96e-02 | 4.21e-01 | 0.0371 |
| 65108 | MARCKSL1 | P9 | Human | Prostate | Tumor | 8.06e-03 | 5.12e-01 | -0.0285 |
| 65108 | MARCKSL1 | P10 | Human | Prostate | Tumor | 1.14e-03 | 1.11e+00 | -0.0902 |
| 65108 | MARCKSL1 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 7.09e-07 | -3.28e-01 | 0.1545 |
| 65108 | MARCKSL1 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 9.50e-03 | -3.17e-01 | 0.1569 |
| 65108 | MARCKSL1 | P5_S10_cSCC | Human | Skin | cSCC | 1.71e-25 | 5.38e-01 | -0.299 |
| 65108 | MARCKSL1 | P1_cSCC | Human | Skin | cSCC | 5.34e-09 | 8.60e-01 | 0.0292 |
| 65108 | MARCKSL1 | P2_cSCC | Human | Skin | cSCC | 1.19e-20 | 1.18e+00 | -0.024 |
| 65108 | MARCKSL1 | P4_cSCC | Human | Skin | cSCC | 5.76e-08 | 6.33e-01 | -0.00290000000000005 |
| 65108 | MARCKSL1 | P10_cSCC | Human | Skin | cSCC | 2.21e-43 | 1.60e+00 | 0.1017 |
| 65108 | MARCKSL1 | cSCC_p7 | Human | Skin | cSCC | 7.56e-05 | -2.61e-01 | -0.2332 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00070159 | Breast | Precancer | actin filament organization | 44/1080 | 442/18723 | 3.02e-04 | 4.35e-03 | 44 |
| GO:000701514 | Breast | IDC | actin filament organization | 55/1434 | 442/18723 | 2.45e-04 | 3.84e-03 | 55 |
| GO:000701524 | Breast | DCIS | actin filament organization | 56/1390 | 442/18723 | 5.90e-05 | 1.19e-03 | 56 |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:000701515 | Cervix | HSIL_HPV | actin filament organization | 43/737 | 442/18723 | 4.77e-08 | 3.59e-06 | 43 |
| GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
| GO:00070151 | Colorectum | SER | actin filament organization | 134/2897 | 442/18723 | 1.39e-15 | 5.70e-13 | 134 |
| GO:00070152 | Colorectum | MSS | actin filament organization | 146/3467 | 442/18723 | 1.16e-13 | 2.67e-11 | 146 |
| GO:00070153 | Colorectum | MSI-H | actin filament organization | 50/1319 | 442/18723 | 6.19e-04 | 1.21e-02 | 50 |
| GO:00070154 | Colorectum | FAP | actin filament organization | 125/2622 | 442/18723 | 1.97e-15 | 3.03e-12 | 125 |
| GO:000701516 | Endometrium | AEH | actin filament organization | 98/2100 | 442/18723 | 1.99e-11 | 2.98e-09 | 98 |
| GO:000701517 | Endometrium | EEC | actin filament organization | 95/2168 | 442/18723 | 1.31e-09 | 1.09e-07 | 95 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:000701512 | Liver | Cirrhotic | actin filament organization | 171/4634 | 442/18723 | 3.93e-11 | 2.30e-09 | 171 |
| GO:000701522 | Liver | HCC | actin filament organization | 252/7958 | 442/18723 | 3.83e-10 | 1.25e-08 | 252 |
| GO:000701532 | Liver | Cyst | actin filament organization | 24/496 | 442/18723 | 7.70e-04 | 2.07e-02 | 24 |
| GO:00070158 | Lung | IAC | actin filament organization | 92/2061 | 442/18723 | 1.01e-09 | 1.93e-07 | 92 |
| GO:000701520 | Oral cavity | OSCC | actin filament organization | 230/7305 | 442/18723 | 1.37e-08 | 2.77e-07 | 230 |
| GO:0007015110 | Oral cavity | LP | actin filament organization | 143/4623 | 442/18723 | 1.44e-04 | 1.65e-03 | 143 |
| GO:000701518 | Prostate | BPH | actin filament organization | 147/3107 | 442/18723 | 3.36e-18 | 1.15e-15 | 147 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0514012 | Breast | IDC | Leishmaniasis | 16/867 | 77/8465 | 4.35e-03 | 2.57e-02 | 1.92e-02 | 16 |
| hsa0514013 | Breast | IDC | Leishmaniasis | 16/867 | 77/8465 | 4.35e-03 | 2.57e-02 | 1.92e-02 | 16 |
| hsa0514021 | Breast | DCIS | Leishmaniasis | 17/846 | 77/8465 | 1.29e-03 | 9.06e-03 | 6.67e-03 | 17 |
| hsa0514031 | Breast | DCIS | Leishmaniasis | 17/846 | 77/8465 | 1.29e-03 | 9.06e-03 | 6.67e-03 | 17 |
| hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
| hsa046661 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
| hsa046662 | Colorectum | SER | Fc gamma R-mediated phagocytosis | 39/1580 | 97/8465 | 5.84e-07 | 9.70e-06 | 7.04e-06 | 39 |
| hsa046663 | Colorectum | SER | Fc gamma R-mediated phagocytosis | 39/1580 | 97/8465 | 5.84e-07 | 9.70e-06 | 7.04e-06 | 39 |
| hsa046664 | Colorectum | MSS | Fc gamma R-mediated phagocytosis | 45/1875 | 97/8465 | 9.30e-08 | 1.56e-06 | 9.55e-07 | 45 |
| hsa046665 | Colorectum | MSS | Fc gamma R-mediated phagocytosis | 45/1875 | 97/8465 | 9.30e-08 | 1.56e-06 | 9.55e-07 | 45 |
| hsa046666 | Colorectum | FAP | Fc gamma R-mediated phagocytosis | 35/1404 | 97/8465 | 2.46e-06 | 4.28e-05 | 2.60e-05 | 35 |
| hsa046667 | Colorectum | FAP | Fc gamma R-mediated phagocytosis | 35/1404 | 97/8465 | 2.46e-06 | 4.28e-05 | 2.60e-05 | 35 |
| hsa0466614 | Endometrium | AEH | Fc gamma R-mediated phagocytosis | 27/1197 | 97/8465 | 3.02e-04 | 2.39e-03 | 1.75e-03 | 27 |
| hsa0466615 | Endometrium | AEH | Fc gamma R-mediated phagocytosis | 27/1197 | 97/8465 | 3.02e-04 | 2.39e-03 | 1.75e-03 | 27 |
| hsa0466621 | Endometrium | EEC | Fc gamma R-mediated phagocytosis | 27/1237 | 97/8465 | 5.15e-04 | 3.83e-03 | 2.85e-03 | 27 |
| hsa0466631 | Endometrium | EEC | Fc gamma R-mediated phagocytosis | 27/1237 | 97/8465 | 5.15e-04 | 3.83e-03 | 2.85e-03 | 27 |
| hsa0466620 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
| hsa04666110 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
| hsa0466610 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
| hsa0466611 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MARCKSL1 | SNV | Missense_Mutation | c.356N>G | p.Ser119Cys | p.S119C | P49006 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MARCKSL1 | SNV | Missense_Mutation | c.480N>T | p.Glu160Asp | p.E160D | P49006 | protein_coding | tolerated(0.06) | probably_damaging(0.95) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MARCKSL1 | SNV | Missense_Mutation | c.310N>C | p.Ser104Pro | p.S104P | P49006 | protein_coding | tolerated(0.08) | possibly_damaging(0.518) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MARCKSL1 | SNV | Missense_Mutation | c.191C>T | p.Ala64Val | p.A64V | P49006 | protein_coding | deleterious(0.01) | benign(0.037) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD | |
| MARCKSL1 | SNV | Missense_Mutation | c.320N>T | p.Arg107Ile | p.R107I | P49006 | protein_coding | deleterious(0) | possibly_damaging(0.701) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MARCKSL1 | SNV | Missense_Mutation | rs770620654 | c.276N>A | p.Phe92Leu | p.F92L | P49006 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MARCKSL1 | SNV | Missense_Mutation | rs770620654 | c.276C>A | p.Phe92Leu | p.F92L | P49006 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MARCKSL1 | SNV | Missense_Mutation | rs770620654 | c.276N>A | p.Phe92Leu | p.F92L | P49006 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| MARCKSL1 | SNV | Missense_Mutation | novel | c.565G>A | p.Ala189Thr | p.A189T | P49006 | protein_coding | tolerated(0.06) | benign(0.077) | TCGA-EY-A1GF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MARCKSL1 | insertion | Frame_Shift_Ins | rs749563695 | c.246dupC | p.Lys83GlnfsTer33 | p.K83Qfs*33 | P49006 | protein_coding | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 65108 | MARCKSL1 | KINASE | IFN | 11483670 | ||
| 65108 | MARCKSL1 | KINASE | IL-6 | 11483670 | ||
| 65108 | MARCKSL1 | KINASE | PMA | 8596017 | ||
| 65108 | MARCKSL1 | KINASE | TNF-ALPHA | 11483670 | ||
| 65108 | MARCKSL1 | KINASE | STAUROSPORINE | STAUROSPORINE | 1730592 | |
| 65108 | MARCKSL1 | KINASE | HERBIMYCIN A | 11483670 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |